Spread of efflux pump overexpressing-mediated fluoroquinolone resistance and multidrug resistance in Pseudomonas aeruginosa by using an efflux pump inhibitor

Infection and Chemotherapy

Volumn 47, Issue 2, 2015, Pages 98-104

  Adabi, Maryam ^a   Talebi Taher, Mahshid ^a   Arbabi, Leila ^a   Afshar, Mastaneh ^a   Fathizadeh, Sara ^a   Minaeian, Sara ^a   Moghadam Maragheh, Niloufar ^b   Majidpour, Ali ^a  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antibiotic therapy; Burned patients; Carbonyl cyanide m chlorophenyl hydrazone; Ciprofloxacin; Efflux pump; Pseudomonas aeruginosa

Indexed keywords

CARBONYL CYANIDE CHLOROPHENYLHYDRAZONE; CEFEPIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL SECRETION SYSTEM; BACTERIAL STRAIN; BACTERIUM ISOLATE; BURN; DISK DIFFUSION; HUMAN; IRAN; MAJOR CLINICAL STUDY; MEXA GENE; MEXC GENE; MEXE GENE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; POLYMERASE CHAIN REACTION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION;

EID: 84936971678     PISSN: 20932340     EISSN: 20926448     Source Type: Journal    
DOI: 10.3947/ic.2015.47.2.98     Document Type: Article

References (23)

1. Askoura M, Mottawea W, Abujamel T, Taher I. Efflux pump inhibitors (EPIs) as new antimicrobial agents against Pseudomonas aeruginosa. Libyan J Med 2011;6:5870.
2. Fagon JY, Chastre J, Wolff M, Gervais C, Parer-Aubas S, Stéphan F, Similowski T, Mercat A, Diehl JL, Sollet JP, Tenaillon A. Invasive and non-invasive strategies for management of suspected ventilator associated pneumonia. Ann Intern Med 2000;132:621-30.
3. Harris A, Torres-Viera L, Vekataraman L, DeGirolami P, Samore M, Carmeli Y. Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa. Clin Infect Dis 1999;28:1128-33.
4. Hancock RE. Resistance mechanisms in Pseudomonas aeruginosa and other non fermentative gram-negative bacteria. Clin Infect Dis 1998;27 (Suppl 1):S93-9.
5. Sefton AM. Mechanisms of antimicrobial resistance: their clinical relevance in the new millennium. Drugs 2002;62:557-66.
6. Kriengkauykiat J, Porter E, Lomovskaya O, Wong-Beringer A. Use of an efflux pump inhibitor to determine the prevalence of efflux pump-mediated fluoroquinolone resistance and multidrug resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005;49:565-70.
7. Köhler T, Michea-Hamzehpour M, Plesiat P, Kahr AL, Pechere JC. Differential selection of multidrug efflux systems by quinolones in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1997;41:2540-3.
8. Chuanchuen R, Narasaki CT, Schweizer HP. The MexJK efflux pump of Pseudomonas aeruginosa requires OprM for antibiotic efflux but not for efflux of triclosan. J Bacteriol 2002;184:5036-44.
9. Li Y, Mima T, Komori Y, Morita Y, Kuroda T, Mizushima T, Tsuchiya T. A new member of the tripartite multidrug efflux pumps, MexVW-OprM, in Pseudomonas aeruginosa. J Antimicrob Chemother 2003;52:572-5.
10. Poole K. Efflux-mediated resistance to fluoroquinolones in gram negative bacteria. Antimicrob Agents Chemother 2000;44:2233-41.
11. Gotoh N, Tsujimoto H, Tsuda M, Okamoto K, Nomura A, Wada T, Nakahashi M, Nishino T. Characterization of the MexC-MexD-OprJ multidrug efflux system in Delta-mexA-mexB-oprM mutants of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1998;42:1938-43.
12. Schweizer H.P. Efflux as a mechanism of resistance to antimicrobials in Pseudomonas aeruginosa and related bacteria: unanswered question. Genet Mol Res 2003;2:48-62.
13. Ikonomidis A, Tsakris A, Kanellopoulou M, Maniatis AN, Pournaras S. Effect of the proton motive force inhibitor carbonyl cyanide-m-chlorophenylhydrazone (CCCP) on Pseudomonas aeruginosa biofilm development. Lett Appl Microbiol 2008;47:298-302.
14. Pagès JM, Masi M, Barbe J. Inhibitors of efflux pumps in Gram-negative bacteria. Trends Mol Med 2005;11:382-9.
15. Barrow G, Feltham R. Characters of gram-negative bacteria in Cowan&steel manual for identification of medical bacteria. 3rd ed. Cambridge, UK: 2003;130-1.
16. De Vos D, Lim A Jr, Pirnay JP, Struelens M, Vandenvelde C, Duinslaeger L, Vanderkelen A, Cornelis P. Direct detection and identification of Pseudomonas aeruginosa in clinical samples such as skin biopsy specimens and expectorations by multiplex PCR based on two outer membrane lipoprotein genes, oprI and oprL. J Clin Microbiol 1997;35:1295-9.
17. Hancock RE, Nikaido H. Outer membranes of gram-negative bacteria. XIX. Isolation from Pseudomonas aeruginosa PAO1 and use in reconstitution and definition of the permeability barrier. J Bacteriol 1978;136:381-90.
18. Pournaras S, Maniati M, Spanakis N, Ikonomidis A, Tassios PT, Tsakris A, Legakis NJ, Maniatis AN. Spread of efflux pump-overexpressing, non-metallo-beta-lactamase-producing, meropenem-resistant but ceftazidime-susceptible Pseudomonas aeruginosa in a region with blaVIM endemicity. J Antimicrob Chemother 2005;56:761-4.
19. Bonfiglio G, Carciotto V, Russo G, Stefani S, Schito GC, Debbia E, Nicoletti G. Antibiotic resistance in Pseudomonas aeruginosa: an Italian survey. J Antimicrob Chemother 1998;41:307-10.
20. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-second informational supplement. Wayne, PA: CLSI;2010.
21. Masuda N, Sakagawa E, Ohya S, Gotho N, Tsujimoto H, Nishino T. Substrate specificities of MexAB-OprM, Mex-CD-OprJ, and MexXY-OprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000;44:3322-7.
22. Quale J, Bratu S, Landman D, Heddurshetti R. Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii endemic in New York City. Clin Infect Dis 2003;37:214-20.
23. Lomovskaya O, Warren MS, Lee A, Galazzo J, Fronko R, Lee M, Blais J, Cho D, Chamberland S, Renau T, Leger R, Hecker S, Watkins W, Hoshino K, Ishida H, Lee VJ. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother 2001;45:105-16.